News
Otolith Labs Announces $20 Million Series A Financing. Otolith Receives Breakthrough Device Designation from FDA. Otolith Receives ISO 13485 Certification for Medical Devices Quality Management Systems from BSI. NASA iTech 2020 Cycle 1 Winner.

Otolith Labs makes non-invasive wearable technology for vertigo, targeting vestibular migraine without surgery or fitting.
otolithlabs.comCrawled Oct 14, 2026
Otolith Labs Announces $20 Million Series A Financing. Otolith Receives Breakthrough Device Designation from FDA. Otolith Receives ISO 13485 Certification for Medical Devices Quality Management Systems from BSI. NASA iTech 2020 Cycle 1 Winner.
Otolith Labs was founded by Sam Owen in 2015. It conducted its first clinical study in 2016, and Land Rover Jaguar validated its motion-sickness technology in 2018.
Otolith Labs is located at 200 Massachusetts Ave NW, Floor 7, Washington, DC 20001.
Otolith Labs is developing a medical wearable to treat chronic vertigo. Its technology is noninvasive and designed to be easy to use.
Otolith Labs presents data showing its technology reduces cybersickness in virtual reality users. The exploratory study, published in *Frontiers*, a leading peer-reviewed journal, examines the effectiveness of Otolith’s approach in mitigating VR-induced discomfort. Findings suggest potential for broader applications in immersive technology.
Otolith Labs secures an additional $20 million in funding. The medtech wearables startup, backed by Mark Cuban, expands its financial support under founder Sam Owen’s leadership. Details on the investment terms or use of funds are not disclosed in the announcement.
Otolith Labs secures $20 million in Series A funding to advance its wearable headband designed for chronic vertigo treatment. The round is led by Morningside Ventures, supporting the company’s focus on digital health solutions.
Otolith Labs secures **$20 million** in funding to advance its **wearable device for vertigo treatment**. The company navigates the dual challenges of product development and regulatory compliance common to medtech startups. The funding supports scaling production and clinical validation for its non-invasive solution targeting balance disorders.
Otolith Labs secures $20 million in Series A funding from Mark Cuban to advance its vertigo-treatment headband. The DC-based startup plans a commercial launch in 2024. The device targets vertigo patients with a hardware-based solution.